Nuclear fusion technology company SHINE Technologies LLC announced that Tom D’Orazio would become CEO of Phoenix LLC, the industrial imaging arm of its business.
D’Orazio most recently was chief operating officer of Tryp Therapeutics, a clinical-stage pharmaceutical company, according to a press release. He has more than 20 years of experience in sales leadership roles for startups and established companies in the health care, biotech and software industries.
Janesville-based SHINE Technologies CEO Greg Piefer founded Phoenix LLC in 2005 to develop and commercialize a unique technology that generated neutrons through fusion. SHINE spun out of Phoenix in 2010 but announced in April 2021 that it had merged with the company.
Phoenix represents phase one – advanced industrial imaging – of SHINE’s four-phase plan to eventually produce clean fusion energy. It uses neutrons for detailed imaging to improve the quality and safety of products in industries including aerospace and energy, SHINE Technologies said in an email.
Both companies are wholly owned subsidiaries of Illuminated Holdings, according to the release.
“As a proven leader for science-driven companies, Tom will be a great addition to Phoenix,” Piefer said in the release. “Along with the announcement of a contract with the Department of Homeland Security earlier this year, Phoenix has signed several new imaging contracts this year. With his leadership and experience, Tom will continue to build on that momentum.”
D’Orazio succeeds Jess Giffey, interim CEO of Phoenix, who will continue as general manager of SHINE’s systems and manufacturing division, the release said.
A Loyola University of Chicago and Vanderbilt University alumnus, D’Orazio has also been CEO and president at scientific services and research organization ImmnoPrecise Antibodies.
